opdualag-hcp-us-main-nav
opdualag-hcp-us-utility-nav

For U.S. Healthcare Professionals only

Next Page Icon

Indication

Fixed-dose
combination
infusion schedule

Actor portrayal.

Opdualag™ (nivolumab and relatlimab-rmbw) is a fixed-dose combination administered as a 30-minute intravenous infusion every 4 weeks1

gradient
Opdualag™ dosing schedule, graphic

*12 years of age or older who weigh at least 40 kg. The recommended dosage for pediatric patients 12 years of age or older who weigh less than 40 kg, and pediatric patients younger than 12 years of age has not been established.1

gradient

A single, fixed-dose infusion may help reduce preparation and infusion times and could help minimize potential risk of administration errors2†

gradient
  • Opdualag is a fixed-dose combination: a co-formulation of 2 active ingredients in a single vial administered as a single infusion1,3

  • A single-dose vial contains 240 mg of nivolumab and 80 mg of relatlimab per 20 mL1
2 Opdualag™ vials

Two vials are required for the nivolumab 480 mg + relatlimab 160 mg indication dose.1

Opdualag can cause severe infusion-related reactions. Discontinue Opdualag in patients with severe or life-threatening infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild or moderate infusion-related reactions (for more information, see the Dosage and Administration Section in the Opdualag Full Prescribing Information). In patients who received Opdualag as a 60-minute intravenous infusion, infusion-related reactions occurred in 7% (n=23/355) of patients.1

Checklist icon
Preparation &
Administration

Find information about how to prepare and administer Opdualag to your patients.

Drip bag icon
Treatment Modifications

Find information about treatment modifications and IMAR management.

References:

  1. Opdualag [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24-34.
  3. Code of Federal Regulations. § 300.50 Fixed-combination prescription drugs for humans. Published January 6, 2022. Accessed February 23, 2022. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-300/subpart-B/section-300.50